论文部分内容阅读
目的观察奥扎格雷钠联合降栓酶治疗脑血栓的临床疗效。方法选取自2011年2月至2013年10月间来黑龙江省双鸭山煤炭总医院就诊的患有脑血栓的200例患者作为研究对象,随机分为对照组和观察组,每组100例。对照组患者采用奥扎格雷钠,观察组采用奥扎格雷钠联合降栓酶,两组均治疗4周。治疗前后抽取5 ml静脉血,检测患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C);治疗总有效率以及不良反应发生率。采用SPSS 13.0软件加以统计、处理以及分析,计数资料用率表示,采用x~2检验,P<0.05为差异有统计学意义。结果观察组显效70例,有效患者17例,无效患者3例,总有效率87%。对照组显效51例,有效患者11例,无效患者8例,总有效率82%。两组相比差异有统计学意义(x~2=4.16,P<0.05)。观察组和治疗组治疗后TC、TG、LDL-C水平均低于治疗前,HDL-C水平高于治疗前,差异有统计学意义(均P<0.05),但观察组变化情况明显优于对照组,组间比较差异有统计学意义(P<0.05)。观察组发生过敏反应4例,呼吸困难3例,眼结膜出血2例,不良反应发生率为9%,对照组发生过敏反应8例,呼吸困难3例,眼结膜出血5例,不良反应发生率为16%,两组相比差异有统计学意义(x~2=5.27,P<0.05)。结论临床上的脑血栓治疗中,奥扎格雷钠联合降栓酶相对于其他传统疗法有着起效快,疗效明显,不良反应较轻且发生几率小以及患者停药后病情不易复发等优点,适于推广。
Objective To observe the clinical efficacy of sodium ozagrel combined with thrombinase in the treatment of cerebral thrombosis. Methods From February 2011 to October 2013, 200 patients with cerebral thrombosis who came to the Shuangyashan Coal General Hospital in Heilongjiang Province were selected as the control group and the observation group, with 100 cases in each group. Patients in the control group were given sodium ozagrel, and sodium ozagrel combined with desmear in the observation group. Both groups were treated for 4 weeks. Before and after treatment, 5 ml of venous blood was drawn and the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol Adverse reaction rate. Using SPSS 13.0 software to statistics, processing and analysis, said the use of counting data, using x ~ 2 test, P <0.05 for the difference was statistically significant. Results The observation group was markedly effective in 70 cases, effective in 17 cases, invalid in 3 cases, the total effective rate was 87%. In the control group, 51 cases were markedly effective, 11 cases were effective, 8 cases were ineffective and the total effective rate was 82%. The difference between the two groups was statistically significant (x ~ 2 = 4.16, P <0.05). The levels of TC, TG and LDL-C in the observation group and the treatment group were lower than those before treatment, and the levels of HDL-C were higher than those before treatment (all P <0.05), but the changes in the observation group were obviously better than The control group, the difference between the groups was statistically significant (P <0.05). There were 4 cases of allergic reaction, 3 cases of dyspnea, 2 cases of conjunctival hemorrhage, 9% of adverse reactions, 8 cases of allergic reaction in control group, 3 cases of dyspnea, 5 cases of conjunctival hemorrhage, the incidence of adverse reactions Was 16%, the difference between the two groups was statistically significant (x ~ 2 = 5.27, P <0.05). Conclusion Clopidogrel sodium combined with desmopressin has the advantages of quick onset, obvious curative effect, mild adverse reactions and low probability of recurrence compared with other traditional therapies in clinical treatment of cerebral thrombosis. In the promotion.